ESR1 and metastatic malignant neoplasm in the lymph nodes: However, there was no statistical difference in TP53 mutation rate (89.3% vs. 87.1%), SEIC (16.7% vs. 6.5%), positive rate of ER (47.5% vs. 61.3%), myometrial invasion ≥ 1/2 (46.7% vs. 32.3%), lymph-vascular space invasion(LVSI) (49.2% vs. 45.2%), or lymph node metastasis (41.8% vs. 20.7%) between the two groups.